Akt1, EMSY, BRCA2 and type I IFN signaling: A novel arm of the IFN response

Transcription

Volumn 3, Issue 6, 2012, Pages

  Ezell, Scott A ^a,b   Tsichlis, Philip N ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Akt; BRCA2; EMSY; Interferon stimulated gene (ISG); IRF9; ISRE; JAK STAT pathway

Indexed keywords

BRCA2 PROTEIN; GLUCOCORTICOID RECEPTOR; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; INTERFERON; JANUS KINASE; MEMBRANE PROTEIN; PROTEIN AKT1; PROTEIN AKT3; PROTEIN EMSY; PROTEIN KINASE B BETA; REPRESSOR PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; UNCLASSIFIED DRUG; C11ORF30 PROTEIN, HUMAN; INTERFERON REGULATORY FACTOR 9; NUCLEAR PROTEIN; PROTEIN KINASE B; TUMOR PROTEIN;

ACETYLATION; ARTICLE; CELL MEMBRANE; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DISULFIDE BOND; FIBROBLAST; GENE OVEREXPRESSION; GLYCOSYLATION; HISTONE ACETYLATION; HUMAN; NONHUMAN; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN INDUCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEOMICS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; AKT; BRCA2; EMSY; GENETIC TRANSCRIPTION; GENETICS; INTERFERON-STIMULATED GENE (ISG); ISRE; JAK/STAT PATHWAY; METABOLISM;

AKT; BRCA2; EMSY; INTERFERON-STIMULATED GENE (ISG); IRF9; ISRE; JAK/STAT PATHWAY;

BRCA2 PROTEIN; HUMANS; INTERFERONS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84872179949     PISSN: 21541264     EISSN: 21541272     Source Type: Journal    
DOI: 10.4161/trans.21904     Document Type: Article

References (42)

1. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007; 6:975-90; PMID:18049472; http://dx.doi.org/10.1038/nrd2422.
2. de Weerd NA, Nguyen T. The interferons and their receptors--distribution and regulation. Immunol Cell Biol 2012; 90:483-91; PMID:22410872; http://dx.doi.org/10.1038/icb.2012.9.
3. Horvath CM, Stark GR, Kerr IM, Darnell JE Jr. Interactions between STAT and non-STAT proteins in the interferon-stimulated gene factor 3 transcription complex. Mol Cell Biol 1996; 16:6957-64; PMID:8943351.
4. Tang X, Gao JS, Guan YJ, McLane KE, Yuan ZL, Ramratnam B, et al. Acetylation-dependent signal transduction for type I interferon receptor. Cell 2007; 131:93-105; PMID:17923090; http://dx.doi.org/10.1016/j.cell.2007.07.034.
5. Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D'Andrea A, et al. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature 1996; 383:344-7; PMID:8848048; http://dx.doi.org/10.1038/383344a0.
6. Kadota S, Nagata K. pp32, an INHAT component, is a transcription machinery recruiter for maximal induction of IFN-stimulated genes. J Cell Sci 2011; 124:892-9; PMID:21325029; http://dx.doi.org/10.1242/jcs.078253.
7. Icardi L, Lievens S, Mori R, Piessevaux J, De Cauwer L, De Bosscher K, et al. Opposed regulation of type I IFN-induced STAT3 and ISGF3 transcriptional activities by histone deacetylases (HDACS) 1 and 2. FASEB J 2012; 26:240-9; PMID:21957129; http://dx.doi.org/10.1096/fj.11-191122.
8. Chang HM, Paulson M, Holko M, Rice CM, Williams BR, Marié I, et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci U S A 2004; 101:9578-83; PMID:15210966; http://dx.doi.org/10.1073/pnas.0400567101.
9. Génin P, Morin P, Civas A. Impairment of interferon-induced IRF-7 gene expression due to inhibition of ISGF3 formation by trichostatin A. J Virol 2003; 77:7113-9; PMID:12768031; http://dx.doi.org/10.1128/JVI.77.12.7113-7119.2003.
10. Mowen KA, Tang J, Zhu W, Schurter BT, Shuai K, Herschman HR, et al. Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell 2001; 104:731-41; PMID:11257227; http://dx.doi.org/10.1016/S0092-8674(01)00269-0.
11. Zhu W, Mustelin T, David M. Arginine methylation of STAT1 regulates its dephosphorylation by T cell protein tyrosine phosphatase. J Biol Chem 2002; 277:35787-90; PMID:12171910; http://dx.doi.org/10.1074/jbc.C200346200.
12. Komyod W, Bauer UM, Heinrich PC, Haan S, Behrmann I. Are STATS arginine-methylated? J Biol Chem 2005; 280:21700-5; PMID:15826948; http://dx.doi.org/10.1074/jbc.C400606200.
13. Meissner T, Krause E, Lödige I, Vinkemeier U. Arginine methylation of STAT1: a reassessment. Cell 2004; 119:587-9, discussion 589-90; PMID:15550240; http://dx.doi.org/10.1016/S0092-8674(04)01090-6.
14. Fang TC, Schaefer U, Mecklenbrauker I, Stienen A, Dewell S, Chen MS, et al. Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. J Exp Med 2012; 209:661-9; PMID:22412156; http://dx.doi.org/10.1084/jem.20112343.
15. Testoni B, Schinzari V, Guerrieri F, Gerbal-Chaloin S, Blandino G, Levrero M. p53-paralog DNp73 oncogene is repressed by IFNα/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. Oncogene 2011; 30:2670-8; PMID:21399658; http://dx.doi.org/10.1038/onc.2010.635.
16. Scott R, Siegrist F, Foser S, Certa U. Interferon-alpha induces reversible DNA demethylation of the interferon-induced transmembrane protein-3 core promoter in human melanoma cells. J Interferon Cytokine Res 2011; 31:601-8; PMID:21413873; http://dx.doi.org/10.1089/jir.2010.0134.
17. Flammer JR, Dobrovolna J, Kennedy MA, Chinenov Y, Glass CK, Ivashkiv LB, et al. The type I interferon signaling pathway is a target for glucocorticoid inhibition. Mol Cell Biol 2010; 30:4564-74; PMID:20679482; http://dx.doi.org/10.1128/MCB.00146-10.
18. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129:1261-74; PMID:17604717; http://dx.doi.org/10.1016/j.cell.2007.06.009.
19. Kaur S, Sassano A, Joseph AM, Majchrzak-Kita B, Eklund EA, Verma A, et al. Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling. J Immunol 2008; 181:7316-23; PMID:18981154.
20. Kaur S, Sassano A, Dolniak B, Joshi S, Majchrzak-Kita B, Baker DP, et al. Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci U S A 2008; 105:4808-13; PMID:18339807; http://dx.doi.org/10.1073/pnas.0710907105.
21. Ezell SA, Polytarchou C, Hatziapostolou M, Guo A, Sanidas I, Bihani T, et al. The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY. Proc Natl Acad Sci U S A 2012; 109:E613-21; PMID:22315412; http://dx.doi.org/10.1073/pnas.1115029109.
22. Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003; 115:523-35; PMID:14651845; http://dx.doi.org/10.1016/S0092-8674(03)00930-9.
23. Tripathi MK, Chaudhuri G. Down-regulation of UCRP and UBE2L6 in BRCA2 knocked-down human breast cells. Biochem Biophys Res Commun 2005; 328:43-8; PMID:15670748; http://dx.doi.org/10.1016/j.bbrc.2004.12.142.
24. Androulidaki A, Iliopoulos D, Arranz A, Doxaki C, Schworer S, Zacharioudaki V, et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009; 31:220-31; PMID:19699171; http://dx.doi.org/10.1016/j.immuni.2009.06.024.
25. Arranz A, Doxaki C, Vergadi E, Martinez de la Torre Y, Vaporidi K, Lagoudaki ED, et al. Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc Natl Acad Sci U S A 2012; 109:9517-22; PMID:22647600; http://dx.doi.org/10.1073/pnas.1119038109.
26. Garapaty S, Xu CF, Trojer P, Mahajan MA, Neubert TA, Samuels HH. Identification and characterization of a novel nuclear protein complex involved in nuclear hormone receptor-mediated gene regulation. J Biol Chem 2009; 284:7542-52; PMID:19131338; http://dx.doi.org/10.1074/jbc.M805872200.
27. Zhao W, Kruse JP, Tang Y, Jung SY, Qin J, Gu W. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 2008; 451:587-90; PMID:18235502; http://dx.doi.org/10.1038/nature06515.
28. Li Z, Chen L, Kabra N, Wang C, Fang J, Chen J. Inhibition of SUV39H1 methyltransferase activity by DBC1. J Biol Chem 2009; 284:10361-6; PMID:19218236; http://dx.doi.org/10.1074/jbc.M900956200.
29. Moshkin YM, Kan TW, Goodfellow H, Bezstarosti K, Maeda RK, Pilyugin M, et al. Histone chaperones ASF1 and NAP1 differentially modulate removal of active histone marks by LID-RPD3 complexes during NOTCH silencing. Mol Cell 2009; 35:782-93; PMID:19782028; http://dx.doi.org/10.1016/j.molcel.2009.07.020.
30. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8:559-68; PMID:18575461; http://dx.doi.org/10.1038/nri2314.
31. Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 2010; 120:1151-64; PMID:20237412; http://dx.doi.org/10.1172/JCI37223.
32. Pokrovskaja K, Panaretakis T, Grandér D. Alternative signaling pathways regulating type I interferon-induced apoptosis. J Interferon Cytokine Res 2005; 25:799-810; PMID:16375608; http://dx.doi.org/10.1089/jir.2005.25.799.
33. Yu F, Ng SS, Chow BK, Sze J, Lu G, Poon WS, et al. Knockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells. J Neurooncol 2011; 103:187-95; PMID:20838853; http://dx.doi.org/10.1007/s11060-010-0377-4.
34. Hatano H, Kudo Y, Ogawa I, Tsunematsu T, Kikuchi A, Abiko Y, et al. IFN-induced transmembrane protein 1 promotes invasion at early stage of head and neck cancer progression. Clin Cancer Res 2008; 14:6097-105; PMID:18829488; http://dx.doi.org/10.1158/1078-0432.CCR-07-4761.
35. Lee J, Goh SH, Song N, Hwang JA, Nam S, Choi IJ, et al. Overexpression of IFITM1 has clinicopathologic effects on gastric cancer and is regulated by an epigenetic mechanism. Am J Pathol 2012; 181:43-52; PMID:22609115; http://dx.doi.org/10.1016/j.ajpath.2012.03.027.
36. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A 2008; 105:18490-5; PMID:19001271; http://dx.doi.org/10.1073/pnas.0809242105.
37. Desai SD, Wood LM, Tsai YC, Hsieh TS, Marks JR, Scott GL, et al. ISG15 as a novel tumor biomarker for drug sensitivity. Mol Cancer Ther 2008; 7:1430-9; PMID:18566215; http://dx.doi.org/10.1158/1535-7163.MCT-07-2345.
38. Fumoto S, Shimokuni T, Tanimoto K, Hiyama K, Otani K, Ohtaki M, et al. Selection of a novel drug-response predictor in esophageal cancer: a novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response. Int J Oncol 2008; 32:413-23; PMID:18202764.
39. Longo SL, Griffith C, Glass A, Shillitoe EJ, Post DE. Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter. Cancer Gene Ther 2011; 18:123-34; PMID:20930860; http://dx.doi.org/10.1038/cgt.2010.62.
40. Moussavi M, Fazli L, Tearle H, Guo Y, Cox M, Bell J, et al. Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice. Cancer Res 2010; 70:1367-76; PMID:20145134; http://dx.doi.org/10.1158/0008-5472.CAN-09-2377.
41. Wood LM, Pan ZK, Seavey MM, Muthukumaran G, Paterson Y. The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. Cancer Immunol Immunother 2012; 61:689-700; PMID:22057675; http://dx.doi.org/10.1007/s00262-011-1129-9.
42. Maher SG, Romero-Weaver AL, Scarzello AJ, Gamero AM. Interferon: cellular executioner or white knight? Curr Med Chem 2007; 14:1279-89; PMID:17504213; http://dx.doi.org/10.2174/092986707780597907.